Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
Kymera Therapeutics (NASDAQ: KYMR) will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 3, 2026 at 8:10 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kymera Therapeutics (NASDAQ: KYMR) will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 3, 2026 at 8:10 a.m. ET.
A live webcast and archived replay will be available in the Investors “News and Events” section of the company website.
Details
News Market Reaction – KYMR
On May 27, the day this news came out, KYMR closed 1.15% above the previous close.
Data tracked by StockTitan Argus for the May 27 session.
Key Figures
- Cash balance
- $1.55 billion
- Quarter ended March 31, 2026
- Collaboration revenue
- $34.4 million
- Q1 2026 collaboration revenue
- Net loss
- $69.2 million
- Q1 2026 net loss
- Total operating expenses
- $118.5 million
- Q1 2026 operating expenses
- R&D expenses
- $98.2 million
- Q1 2026 research and development spending
- Milestone payment
- $45 million
- KT-200 option exercise by Gilead, expected Q2 2026 revenue
- FMR ownership
- 11,681,450.45 shares (14.3%)
- FMR LLC Schedule 13G/A as of March 31, 2026
- T. Rowe Price ownership
- 5,460,257 shares (6.7%)
- T. Rowe Price Investment Management Schedule 13G as of March 31, 2026
Historical Context
-
Phase 1b KT-621 data with robust STAT6 degradation and efficacy signals.
-
Announcement of May healthcare conference fireside chat participation.
-
Preclinical KT-579 IBD data showing reduced disease activity and cytokine inhibition.
-
Jeito Capital leadership appointments in life-sciences investment management.
-
Q1 2026 results with higher collaboration revenue, wider loss, and large cash balance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY on June 3, 2026, at 8:10 a.m. ET.
A live webcast of the presentation will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Investor Contact:
Justine Koenigsberg
investors@kymeratx.com
857-285-5300
Media Contact:
Matthew Henson
media@kymeratx.com
857-285-5300
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.